Ad26.RSV.preF

AXP000175.1 · Vaccine

Platform
human adenovirus 26 (non-replicating)
Targets
RSV F
Originator
Janssen Vaccines & Prevention
Sponsor
Johnson & Johnson

Names

NameTypeSource
Ad26.RSV.preFpreferred name, codecurator, ctgov
Ad26.RSV.preF-based vaccine ambiguoussynonymctgov

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
human adenovirus 26
Strain
Ad26
Replication
non replicating
Modifications
non-replicating Ad26 encoding a pre-fusion conformation-stabilised RSV F protein
Transgenes
RSV pre-fusion F
Route
intramuscular
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (15)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05242432A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese ParticipantsTerminatedPhase 32022-04-012023-03-202192Respiratory Syncytial Virus Prevention
NCT05101486A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 YearsCompletedPhase 32021-11-012022-03-28755Respiratory Syncytial Virus Prevention
NCT05083585A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years OldCompletedPhase 32021-10-082022-03-07250Respiratory Syncytial Virus Prevention
NCT05071313A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and OlderCompletedPhase 32021-10-042022-04-20777Influenza, Human Prevention; Respiratory Syncytial Viruses Prevention
NCT05070546A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV InfectionCompletedPhase 32021-09-292022-08-121124Respiratory Syncytial Virus Infection Prevention
NCT04908683A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and OlderCompletedPhase 32021-07-212023-07-2125236Lower Respiratory Tract Disease; Respiratory Syncytial Viruses
NCT04453202A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older AdultsCompletedPhase 22020-07-162020-09-24459Healthy
NCT03982199A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and OlderTerminatedPhase 22019-08-012022-06-065815Respiratory Syncytial Viruses; Respiratory Tract Diseases
NCT03606512A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of AgeCompletedPhase 1/22019-01-212021-11-0238Respiratory Syncytial Virus
NCT03795441A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in AdultsCompletedPhase 12019-01-072019-07-2824Healthy
NCT03502707A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and OlderCompletedPhase 1/22018-07-062022-05-16669Healthy
NCT03339713A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable HealthCompletedPhase 22017-12-072018-07-23180Healthy
NCT03303625A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of AgeCompletedPhase 1/22017-11-292020-04-2148Respiratory Syncytial Viruses; Respiratory Tract Infections
NCT03334695An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old AdultsCompletedPhase 22017-10-162018-07-1064Healthy
NCT02926430A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable HealthCompletedPhase 12016-11-082018-03-1473Healthy

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42061096A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines.EBioMedicine2026name in abstract: Ad26.RSV.preF
PMID 42981739A randomised, double-blind, multicentre, placebo-controlled phase 3 efficacy, safety, and immunogenicity study of an Ad26.RSV.preF/RSV prefusion F-protein vaccine for the prevention of respiratory syncytial virus-mediated lower respiratory tract disease in adults aged 60 years and older.EBioMedicine2026cited by trial NCT04908683
PMID 39536455Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.Vaccine2025cited by trial NCT05070546
PMID 39971605Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas.BMJ open2025cited by trial NCT05070546
PMID 40319702Phase 3 study of an Ad26.RSV.preF/RSV preF protein vaccine to evaluate the prevention efficacy of RSV-mediated lower tract disease, immunogenicity and safety in Japanese adults.Respiratory investigation2025cited by trial NCT05242432
PMID 37433021Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.The Journal of infectious diseases2024cited by trial NCT03502707
PMID 38134393Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial.The Journal of infectious diseases2024name in title: Ad26.RSV.preF
PMID 38783590Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life.Human vaccines & immunotherapeutics2024name in title: Ad26.RSV.preF
PMID 38801826Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.The Lancet. Infectious diseases2024cited by trial NCT03982199
PMID 38880785A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older.Influenza and other respiratory viruses2024name in title: Ad26.RSV.preF
PMID 38902186Parental knowledge and attitudes to infant immunization in the context of RSV: All about confidence?Vaccine2024cited by trial NCT04908683
PMID 39220658A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months.Open forum infectious diseases2024cited by trial NCT03606512
PMID 39276619Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study.Vaccine2024cited by trial NCT04453202
PMID 36791161Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.The New England journal of medicine2023cited by trial NCT03982199
PMID 37902399Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.Journal of virology2023name in title: Ad26.RSV.preF
PMID 33400792Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.The Journal of infectious diseases2022name in title: Ad26.RSV.preF
PMID 36259542Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.The Journal of infectious diseases2022name in abstract: Ad26.RSV.preF
PMID 32851411Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.The Journal of infectious diseases2021cited by trial NCT03339713
PMID 32320465Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.The Journal of infectious diseases2020name in title: Ad26.RSV.preF

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41601003Adenovector 26 Encoded RSV Prefusion F Protein (Ad26.RSV.preF) Does Not Predispose to Enhanced Respiratory Disease in Preclinical Rodent Models.Vaccines2026name in title: Ad26.RSV.preF
PMID 38793751Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Vaccines2024name in abstract: Ad26.RSV.preF
PMID 39118413Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material.Human vaccines & immunotherapeutics2024name in title: Ad26.RSV.preF
PMID 39587114Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge.NPJ vaccines2024name in title: Ad26.RSV.preF
PMID 36949051Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models.NPJ vaccines2023name in title: Ad26.RSV.preF
PMID 37276605In older adults, an Ad26.RSV.preF-RSV preF protein vaccine reduced RSV-related lower respiratory tract disease.Annals of internal medicine2023name in title: Ad26.RSV.preF
PMID 34973849Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.Vaccine2022name in abstract: Ad26.RSV.preF
PMID 36280532Development of mRNA vaccines against respiratory syncytial virus (RSV).Cytokine & growth factor reviews2022name in abstract: Ad26.RSV.preF
PMID 33764693The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.Influenza and other respiratory viruses2021name in abstract: Ad26.RSV.preF
PMID 32566260Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice.NPJ vaccines2020name in abstract: Ad26.RSV.preF

Notes

Ad26 encoding a pre-fusion conformation-stabilised respiratory syncytial virus F protein. Reached phase 3 (EVERGREEN, NCT04908683) in adults aged 60 and over after about 80% efficacy in the phase 2b CYPRESS challenge-free trial; Johnson & Johnson discontinued the programme in 2023. Some trials combined the vector with recombinant preF protein in one regimen.

How to cite

Ad26.RSV.preF (AXP000175.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000175.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.